Clozapine: an atypical antipsychotic agent

Area of Science:

• Pharmacology and Psychiatry
• Neuroscience
• Clinical Therapeutics

Background:

• Clozapine is an atypical antipsychotic drug from the dibenzazepine class.
• It possesses a unique pharmacologic profile distinct from other available medications.
• Clozapine exhibits low potential for extrapyramidal symptoms and does not induce dopamine type 2 receptor hypersensitivity.

Purpose of the Study:

• To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, dosage, and cost of clozapine.
• To evaluate clozapine's therapeutic potential in various psychiatric conditions.
• To compare clozapine's efficacy and safety against other antipsychotic treatments.

Main Methods:

• Review of existing pharmacological and clinical data on clozapine.
• Analysis of in vitro receptor binding affinities (dopamine, histamine, adrenergic, serotonin, muscarinic).
• Examination of data from double-blind comparative studies against haloperidol, chlorpromazine, and placebo.

Main Results:

• Clozapine demonstrates broad receptor affinity and is well-absorbed orally, with metabolites primarily excreted in urine.
• Clinical studies show clozapine superior to haloperidol, chlorpromazine, and placebo in treating schizophrenia symptoms.
• Adverse effects include transient orthostatic hypotension, tachycardia, sedation, and seizures; agranulocytosis risk necessitates monitoring.

Conclusions:

• Clozapine is a highly effective treatment for schizophrenia, particularly refractory cases, with minimal extrapyramidal symptoms.
• Its distinct receptor binding profile contributes to its efficacy and tolerability.
• Despite its cost and risk of agranulocytosis, clozapine's benefits may outweigh drawbacks, especially in treatment-resistant patients.